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ABSTRACT 
Tyr-o-Arg2-Phe-sarcosine4 (TAPS), a mu-selective tetrapeptide 
analog of dermorphin, induced sustained antinociception and 
stimulated ventilatory minute volume (MV) at the doses of 3 to 
100 pmol i.c.v. The doses of 30 and 100 pmol i.c.v. induced 
catalepsy. The effect of TAPS on MV was in negative correlation 
with the dose and the maximal response was achieved by the 
lowest (3 pmol) dose (+63 ± 23°/o, P < .05). Morphine, an 
agonist at both mu, and mu2 sites, at a dose of 150 nmol i.c.v. 
(equianalgetic to 100 pmol of TAPS decreased the MV by 30%, 
due to a decrease in ventilatory tidal volume. The antinociceptive 
effect of TAPS was antagonized by naloxone and the mu, 
receptor antagonist, naloxonazine. Naloxonazine also atten-
uated the catalepsy produced by 1 00 pmol of TAPS i.c. v. and 
the respiratory Stimulation produced by 3 pmol of TAPS i.c.v. 
Dermorphin is a heptapeptide (Tyr-o-Ala-Phe-Gly-Tyr-Pro-
Ser-NH2) derived from amphibian skin. Dermorphin selectively 
binds to mu-opioid receptors (de Castiglione and Rossi, 1985; 
Krumins, 1987) and displays potent opioid effects such as 
analgesia (Broccardo et al., 1981; Stevens and Yaksh, 1986), 
catalepsy and respiratory depression (Paakkari and Feuerstein, 
1988; Paakkari et al., 1990). The N-terminal tetrapeptide of 
dermorphin is the minimum sequence for opioid activity but 
the fragment is less potent than the parent heptapeptide (Broc-
cardo et al., 1981; Salvadori et al., 1982). However, substitution 
of the D-Ala2 residue with D-Arg and Gly4 with sarcosine 
markedly enhances the potency of the tetrapeptide. In antino-
ciceptive tests, TAPS was about 6 tim es as potent as dermor-
phin (Sasaki et al., 1984; de Castiglione and Rossi, 1985; Sato 
et al., 1987). The D-Arg2-Sar4-substitutions also increased bind-
ing of dimeric dermorphin analogs to mu receptors while de-
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Pretreatment with 30 pmol of TAPS antagonized the respiratory 
depression induced by the mu opioid agonist dermorphin 
(changes in MV after dermorphin alone at 1 or 3 nmol were -22 
± 1 0°/o and -60 ± 9% and, after pretreatment with TAPS, +44 
± 11 °/o and -18 ± 5%, respectively). After combined pretreat-
ment with naloxonazine and TAPS, 1 nmol of dermorphin had 
no significant effect on ventilation. ln contrast, pretreatment with 
a low respiratory stimulant dose (10 pmol i.c.v.) of dermorphin 
did not modify the effect of 1 nmol of dermorphin. ln conclusion, 
the antinociceptive, cataleptic and respiratory stimulant effects 
of TAPS appear to be a related to its agonist action at the mu, 
opioid receptors. TAPS did not induce respiratory depression (a 
mu2 opioid effect) but antagonized the respiratory depressant 
effect of another mu agonist. Thus, in vivo TAPS appears to act 
as a mu2 receptor antagonist. 
creasing binding to delta receptors, yielding a very high mu/ 
delta selectivity ratio (Lazarus et al., 1989). 
Opioid analgesia has been suggested to be mediated by the 
mu1 receptors, whereas m~ receptors are thought tobe involved 
in respiratory depression and inhibition of the guinea pig ileum 
contractions (Ling et al., 1985; Gintzler and Pastemak, 1983; 
Pastemak and Wood, 1986). Furthermore, signs of opiate with-
drawal syndrome seem to be mediated through binding sites 
other than mu1 receptors (Ling et al., 1984). Because TAPS 
was more potent than dermorphin in analgesia tests but less 
potent in the guinea pig ileum (Sato et al., 1987) and induced a 
le88 severe withdrawal syndrome than morphine (Nakata et al., 
1986), we proposed that TAPS might stimulate primarily mu1 
receptors and therefore display less respiratory depression than 
dermorphin. To test this hypothesis, the respiratory effects of 
TAPS were compared with those of morphine and dermorphin. 
Pretreatment with the mu1 receptor antagonist naloxonazine 
was used to elucidate the role of mu1 receptors in TAPS- and 
dermorphin-induced antinociceptive, behavioral and respira-
tory changes. 
ABBREVIATION$: TAPS, Tyr-o-Arg2-Phe-sarcosine; MV, minute volume; TV, tidaJ volume; VR, ventilatory rate; ANOVA, analysis of variance. 
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Methods 
Surgical procedures. Male Sprague-Dawley rata (300 ± 40 g, 
Taconic Farms, Germantown, NY) were used in all experimenta. Tbe 
rats were anesthetized with an intramuscular injection of 0.13 ml/100 
g ketamine-acepromazine solution (100 mg/ml of ketamine and 1 mg/ 
ml of acepromazine). A stainless steel guide cannula was stereotaxically 
inserted (David Kopf Instrument, Tujunga, CA) into the rigbt lateral 
brain ventricle and fixed with instant glue (Eastman 910 adhesive, 
Esstman Kodak, Rochester, NY). Coordinates for tbe lateral ventricle 
were AP = -0.8 mm and L = 1.2 mm. After the operation, the rate 
were allowed to recover for 1 to 3 days in separate plastic cages, with 
food and water ad libitum, and a 12/12-hr Iight/dark cycle. On tbe day 
of the experiment, a premeasured 30-g cannula was inserted into the 
ventricular space through the guide cannula. The injection cannula was 
connected by polyethylene tubing to a Hamilton microliter syringe and 
the drug solution was injected over a period of 20 sec in a volume of 10 
,.,1. The proper position of the i.c.v. cannula was ascertained at the end 
of the experiment by dissection of the brain after an injection of 
methylene blue (10 ,.,1). 
Evaluation of antinociceptive and cataleptic effectll. Analgesie 
in rats was determined using a tail flick apparatus (Socrel, Milano, 
Italy). The principle of the radiant heat tail flick technique has been 
described by D'Amour and Smith (1941). Base-line latencies are deter-
mined for each animal and, after drug administration, the reaction 
times are measured repeatedly. A maximal cutofftime of the heat was 
12 sec to prevent tissue damage. 
Catalepsy was evaluated by placing the front Iimba of the rat over a 
10-cm high horizontal bar and measuring the time that the animal 
maintained that posture. lf the rat remained 60 sec on the bar, it was 
defined as cataleptic. In evaluation of the righting reflex, the animals 
were designated as havinglost their righting reflex if they remained in 
a supine position for 10 sec. 
Recording of respiration. The respiration rate and relative res-
piration tidal volume were monitored using the Oxymax 85 system 
(Columbus Instruments, Columbus, OH). This computerized recording 
system consista of two Plexiglas test chambers and one reference 
chamber with a constant flow of room air of 2 Iiters per minute. The 
respiration rate was determined based on the frequency (respirations 
per minute) of pressure changes due to the ventilatory movements of 
the rat's thorax. The TV was recorded as an integral of pulses; this 
was proportional to the amplitude of the pressure changes and com-
pared with the pulse count in the first sample measurement of the 
experiment. The TV therefore was expressed as the relative TV in 
arbitrary units. The relative ventilatory MV was calculated as the 
arithmetical product of the respirationrate and the relative TV. The 
accuracy of the respiration rate recording was ±1 %. The respiratory 
data were gathered at 2-min intervals. 
Initially, the rats were allowed to accommodate for 40 min before 
the administration of drugs. The average of five recordings during 10 
min before the first drug administration was taken as the base-line 
Ievel of ventilation. To minimize the effect on ventilation caused by 
handling the animals during injection procedures, the data were eval-
uated starting 30 min after the drug injection. 
Data proceeeing and •tati•tic•. The data from the recording 
instruments were stored and, in part, processed by the computer 
program Dataquest provided by the manufacturer (Columbua Instru-
ments). In general, averages of five consecutive measurements were 
calculated and median time pointa were used. The calculations of the 
data were carried out in a standard spreadsheet. For statistical analysis 
the CSS: STATISTICA software package (StatSoft, Tulsa, OK) was 
used. The results were expressed as means ± S.E. for five to eight 
experiments. For analysis of the dose-response relationships, the res-
piratory effects of TAPS were assessed as areas under tbe curves of 
the percent changes in relative MV over time (114 min), uaing a 
trapezoidal method. This approximative procedure consista of the 
summation of the areas of various trapezoids fitted to the curve segment 
representing the treatment period. For statistical analysis of data with 
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equal variances, the ANOV A followed by Tukey's multiple comparison 
test or Student's t test were used. The Kruskal-Wallis nonparametric 
ANOV A and the Mann· Whitney U test were used for groups with 
unequal variances. The dose-response curves were analyzed using linear 
regression of all data points rather than the mean responses. The doses 
producing antinociceptive EDao responses were calculated from the 
linear portion of the log of the dose-response curve and the EDao values 
with their associated 95% confidence intervals have been reported. 
Drugs. Dermorphin and TAPS (Peninsula, Belmont, CA), naloxone 
(DuPont Pbarmaceuticals, Wilmington, DE) and naloxonazine (Re-
search Biocbemicals, Natick, MA, and a generaus gift from Dr. G. W. 
Pastemak, Memorial Sloan-Kettering Cancer Center, New York, NY) 
were dissolved in 0.9% saline (naloxonazine with a few drops of glacial 
acetic acid). The final concentration of acetic acid in tbe solution was 
2%, pH 5. Vebicle (2% acetic acid in saline) or naloxonazine (10 or 20 
mg/kg) was administered i.v. 20 to 24 hr before the experiment. Other 
pretreatmenta were injected i.c.v. 20 min before the test drug. 
Results 
Antinociceptive effect ofT APS alter i.c. v. administra-
tion. Administration ofTAPS i.c.v. produced dose-related anti-
nociceptive effects (fig. 1). The dose of 1 pmol (0.5 ng) ofTAPS 
induced a transient increase in the tail-flick latency correspond-
ing to an antinociceptive response of about 20% of the maximal 
possible effect. The dose of 3 pmol (1.7 ng) of TAPS induced 
analgesia, which was about 30% of the maximum possible effect 
and Iasted about 1 hr. Tbe dose of 6 pmol (3.2 ng) produced an 
antinociceptive effect that was 48% of the maximal analgesia. 
After the dose of 10 pmol (5.3 ng) of TAPS, an antinociceptive 
effect of 98% of the maximal possible effect was observed 30 
min after the injection and was still more than 30% of the 
maximal analgesia at 2 hrs postinjection. After the dose of 30 
pmol (17 ng), maximal antinociception was evident 15 min 
after the injection and the antinociception was about 50% of 
the maximal possible effect 2 hr after injection. The highest 
dose tested, 100 pmol (53 ng), produced maximal analgesia that 
Iasted for about 2 hr and the antinociception was more than 
60% of the maximal possible effect 3 hr postinjection (fig. 1). 
The doses of 1, 3, 6, 10 and 30 pmol ofTAPS were plotted into 
a log dose-response curve (fig. 2, upper panel) and the curve 
was analyzed with least squares linear regression yielding a 
positive correlation between dose and effect (slope = 56.802; 
95% confidence interval, 40.273-73.331; r = .805; P < .0001) 
and an ED60 value of 4.1 pmol (95% confidence interval, 2.1-
6.9 pmol). 
The antinociceptive effect of 30 pmol of TAPS was blocked 
by treatment with naloxone (5 mg/kg i.v., fig. 3). Pretreatment 
with naloxonazine (10 or 20 mg/kg i.v.) also attenuated the 
antinociception induced by TAPS doses of 30 pmol (fig. 3) and 
100 pmol (table 1). 
Antinociceptive effect of TAPS after i. v. or p.o. ad-
ministration. TAPS produced dose-related antinociceptive 
effecta after i.v. and p.o. administration (fig. 1). On i.v. admin-
istration, nearly maximal analgesia (97% of the maximal pos-
sible effect) was obtained 30 min after the dose of 1.5 mg/kg 
(2.7 ~tmol/kg). Orally, TAPS doses of 10 and 20 mg/kg (18 and 
36 ~tmol/kg) produced about 60% of maximum analgesia, which 
subsided gradually during 3 hr (fig. 1). When the i.v. doses of 
TAPS were plotted into a log dose-response curve (fig. 2, lower 
panel) and the curve was analyzed with least squares linear 
regression, a positive correlation between dose and effect (slope 
= 80.742; 95% confidence interval, 61.530-99.954; r = .891; P 
< .0001) was found. A positive correlation between dose and 
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Fig. 1. Analgesie effect of TAPS i.c.v. (1, 3, 10, 30 or 100 pmolfrat, 
upper panel, n =5-6 in all groups), i.v. (0.5 or 1.5 mgfkg, middle panel, 
n - 5-6 in all groups) and p.o. (5, 1 0 or 20 mgJkg, lower panel, n = 3 in 
all groups). The results are shown as percents of maximal possäble effect 
(Ofompe). Two-way ANOVA with repeated measures was used to analyze 
the antinociceptive effect of TAPS i.c.v. and i.v., while statistical analysis 
of the analgesia after TAPS p.o. was not done due to the small number 
of animals in these groups (n • 3). After TAPS i.c. v., a significant 
Interaction between time and dose (P < .001) were found at time points 
15, 30 and 120 min. The statistical significances for individual doses 
were analyzed by Tukey's test: 3 pmol of TAPS compared with saline 
(P < .01 ); 10, 30 or 1 00 pmol of TAPS cornpared with saline (P < .001 ). 
After TAPS i. v., a significant Interaction between time and dose (P < 
.001) was found at all time points. The statistical significances for 
individual doses were analyzed by Tukey's test: 0.5, 1 or 1.5 mgfkg of 
TAPS cornpared with saline (P < .001 ). 
effect was also found for oral TAPS (slope = 86.350; 95% 
confidence interval, 42.733-129.968; r = .871; P < .0023). The 
ED60 values calculated from log dose-response curves were 0.8 
#lmol/kg (95% confidence interval, 0.4-1.3 #lmol/kg or 0.43 mg/ 
kg) for TAPS i.v. and 26 #lmol/kg (13.9 mg/kg) for TAPS p.o. 
(fig. 2, lower panel). 
For comparison, the antinociceptive effect of morphine 30 
and 150 nmol i.c.v. was evaluated. After the 30-nmol dose of 
morphine i.c.v., a peak antinociceptive response of 80 ± 11% 
was produced ( n = 6, P < .05 compared with that of saline 
control) of the maximal possible effect, which was reached 60 
min after morphine administration. The higher dose (150 nmol) 
produced nearly maximal analgesia (90 ± 10% to 95 ± 4%, n = 
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Flg. 2. Dose-response relationship of the TAPS-induced antinociceptlon. 
The upper panel depicts the effect of TAPSafter i.c.v. doses of 1, 3, 6, 
10 and 30 pmol; the lower panel depicts the effect of TAPSafter i.v. 
doses of 0.3, 0.9, 1.8 and 2.7 ~tmol/kg or after the p.o. doses of 9, 18 
and 36 ~tmolfkg. The results are shown as percents of the maximal 
possible effect. Unear regression analysis of the curves revealed that 
the slope of each curve was significantly different from zero. The slopes 
wlth 95% confldence Iimits, correlation coefficients and P values for each 
curve were as follows: slope = 56.802, 95% confidence interval, 40.273 
to 73.331, r • .805, P < .0001 (TAPS i.c.v.); slope = 80.742, 95% 
confidence interval, 61.530 to 99.954, r = .891, P < .0001 (TAPS i.v.); 
slope - 86.350, 95% confidence interval, 42.733 to 129.968, r = .871, 
P < .0023 (TAPS p.o.). 
6, P < .05 compared with that of saline control) for more than 
3 hr. 
Cataleptic effect of TAPS alter i.c. v. administration. 
A dose of TAPS of 100 pmol i.c.v. produced catalepsy, which 
Iasted 60 min in all animals. At 180 min, one of the five rats 
was still cataleptic (table 1). After the 30 pmol dose of TAPS 
i.c. v ., three of the six rats (50%) were cataleptic for 15 min and 
two of the six rats (33%) were cataleptic 30 min after injection. 
None of the animals were cataleptic 60 min after the injection. 
At none of the doses tested did the rats lose the righting reflex. 
None of the animals that received TAPS i.c.v. at the doses of 
1, 3, 6 or 10 pmol or the animals that received TAPS i.v. or p.o. 
was cataleptic. 
Pretreatment with naloxonazine (20 mg/kg i.v.) attenuated 
the catalepsy induced by 100 pmol of TAPS (table 1). 
Ventilatory effects ofT APS and morphine alter i.c. v. 
aclministration. Due to the increases in ventilatory TV and 
VR, TAPS doses up to 100 pmol i.c.v. increased ventilatory 
MV (figs. 4 and 5, upper panel). The maximum increase in MV 
after 3 pmol of TAPS was 63 ± 23% (P < .05, compared with 
base-line values). The corresponding effect after 100 pmol was 
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Flg. 3. The analgesic effect of 30 prnol of TAPS i.c.v. in vehicle-treated 
rats (vehicle + TAPS, n = 5), naloxonazine-treated rats (NAZ, 10 mg/kg 
i.v., n = 5) or in naloxone-treated rats (NAL, 5 mg/kg i.v., n = 4). The 
group that received naloxonazine and saline (NAZ + vehicle, n = 4) is 
also shown. • denote statistical significance (Tukey's test) compared 
with the group that received vehicle and TAPS (* P < .05). t indicate 
statistical significance compared with the group that received NAZ and 
vehide r p < .05). 
TABLE 1 
Antagonism by naloxonazine (20 mg/kg l.v.) of analgesia and 
catalepsy induced by TAPS (100 pmol/rat i.c.v.) 
Naloxonazine or vehicle (2% acetic acid in saline) was injected into the right jugular 
vein 20 hr before the administration of TAPS (100 pmolfrat i.c.v.). The data 
represent means ± S.E. of five animals in the contrOI group and seven rats in the 
naloxonazine-treated group. Analgesia data was analyzed using two-way ANOVA 
and Tukey's test; Fisher exact probability test was used to evaluate the catalepsy 
data. 
Vehide + TAPS Naloxonazile +TAPS 
Tme 
Analgesia %Cataleplic ~ %Cataleptic 
mln o/otnplf %n.,e 
30 100 ± 0 100 95 ±4 29* 
60 99 ± 1 100 92±4 29* 
90 98±2 60 57± 11* o· 
120 98 ± 2 60 44±11* o· 
150 93± 5 40 35± 9* 0 
180 67 ± 14 20 28± 7* 0 
210 50± 16 0 16 ± 7* 0 
240 34± 4 0 14 ± 7 0 
• Percent of the maximal possible effect. 
• P < .05 between naloxonazine- and vehicle-treated groups. 
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Flg. 4. Effect of i.c.v. treatments of 30 pmol of TAPS (n = 8), 100 pmol 
(n = 6) or 300 pmol (n = 8), morphine (150 nmol of MOR, n = 7) or 
saline (n • 6) on ventilatory MV, shown as a percent change from the 
base Ievei. One-way ANOVA with repeated measures revealed a signifi-
cant interaction between treatment and time for all time points for 1 00 
pmol of TAPS and 150 pmol of MOA (P < .01 ). 
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Fig. 5. Dose-response relationship of the TAPS effect on MV. The upper 
panel demonstrates the areas under the curve of the time-response 
curves for TAPS and saline as seen in figures 4 and 6. Statistical analysis 
by Kruskai-Wallis nonparametric ANOVA revealed a significant treatment 
effect (P = .03). The Mann-Whitney U test was used for comparisons of 
individual groups. • denote statistical significance compared with the 
saline-treated group (• P < .05 and •• P < .01 ). tt indicate statistical 
significance compared with morphine (' P < .05 and tt P < .01 ). The 
lower panel denotes the corresponding values plotted as a dose-re-
sponse curve. Unear regression analysis of the curve revealed a negative 
correlatlon between dose and effect (slope -14.313: 95% confidence 
interval, -26.092 to -2.535; r - -0.448; P = .019). The number of rats 
at each dose Ievei was n = 5 (3 pmol of TAPS and morphine), n = 6 
(100 pmol of TAPS and saline) and n = 8 (30 and 300 pmol of TAPS). 
39 ± 18% (P < .05 compared with base-line values). The 
changes in MV after saline injection were not significant (figs. 
4 and 5). The areas under the curve for the TAPS-induced 
changes in MV were plottedas a dose-response curve (fig. 5, 
lower panel). Linear regression analysis of the dose-response 
curve (fig. 5, lower panel) yielded a negative correlation between 
dose and effect (slope -14.313; 95% confidence Iimit, -26.092 
to -2.535; r = .448; P = .019). 
The respiratory stimulant effect ofTAPS (3 pmol i.c.v.) was 
attenuated in animals treated with the mu1 antagonist nalox-
onazine (fig. 6). 
Morphine 150 nmol i.c.v. (equianalgetic to 100 pmol ofTAPS 
i.c.v.) depressed MV (maximal decrease -32 ± 8%, P < .05 
compared with saline, fig. 4). The depressant effect of morphine 
was due to a decrease in TV (maximal decrease -40 ± 2%, P 
< .01 compared with base-line values) but morphine had no 
significant effect on VR (fig. 7). 
Effect ofT APS, naloxonazine or dermorphin pretreat-
ment on dermorphin-induced ventilatory depression. 
The interactions of TAPS with the mu-opioid agonist dermor-
phin are summarized in figure 8. Dermorphin alone (3 nmol 
i.c.v.) decreased MV by -60 ± 9% (P < .05 compared with 
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naJoxonazine (NAZ) pretreatment (1 0 mg/kg i. v .) on ventilatory MV. The 
number of rats was six in both groups. The data are expressed as the 
percent change from the base line. Two-way ANOVA revealed a signifi-
cant difference between groups (P < .01) during 34 to 84-min postinjec-
tion. 
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Flg. 7. Effect of 150 nmol of morphine (upper panel, n = 5) or 100 pmol 
of TAPS (lower panel, n • 6) on VR anct TV. The data are shown as the 
percent change from the base line. The morphine-induced depression of 
TV was significant (P < .001) when analyzed by one-way ANOVA with 
repeated measures. 
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Fig. 8. Percent changes in ventilatory MV after dermorphin (DM) doses 
of 1 or 3 nmol in the absence or presence of pretreatments with 30 pmol 
of TAPS, naloxonazine (NAZ 10 mgfkg i.v.) plus 30 pmol of TAPS or DM 
at a dose of 10 pmol. • incticate statistical significance 1 nmol of DM 
compared with TAPS + 1 nmol of DM, •• P < .01 by Tukey's test; 3 
nmol of DM compared with TAPS+ 3 nmol of DM, • P < .05 by Student's 
t test). Number of ratswas five to six in all groups. 
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base-line values). After pretreatment with TAPS (30 pmol 
i.c.v.), the respiratory depressant effect of 3 nmol of dermorphin 
was not significant (-18 ± 5%, not significant compared with 
base-line values). Another dose of dermorphin (1 nmol/rat 
i.c.v.) tended to decrease MV (-22 ± 10%, not significant 
compared with base-line values) when administered after saline 
pretreatment. After pretreatment with TAPS (30 pmol i.c.v.), 
this dermorphin dose increased MV maximally by 44 ± 11% (P 
< .05 compared with base-line values ). After combined pretreat-
ment with naloxonazine plus TAPS, dermorphin (1 nmol i.c.v.) 
bad no effect on respiration. Pretreatment with a low dose (10 
pmol i.c.v.) of dermorphin did not modify the respiratory effect 
dermorphin (1 nmol i.c.v.). 
Discussion 
In the present study, the mu-selective dermorphin tetrapep-
tide, TAPS produced dose-dependent antinociceptive effects 
after i.c.v. administration. At low doses of TAPS i.c.v., the 
T APS-induced antinociception was not accompanied by any 
motor deficits. At the two highest i.c.v. doses tested, 30 pmol 
and 100 pmol, TAPS-induced analgesia was accompanied by 
catalepsy. However, the cataleptic effect ofT APS 30 pmol was 
transient ( 60 min after the injection, .none of the animals was 
cataleptic), whereas a significant antinociceptive effect has 
been observed for more than 2 hr after administration of this 
dose of TAPS. A dose of TAPS of 100 pmol i.c.v. produced 
catalepsy that Iasted 1 hr in all animals; nearly maximal anal-
gesia was observed for 3 hr. In a previous study, another mu-
agonist dermorphin (90 pmol i.c.v.) produced catalepsy in 85% 
of rats with the average duration of catalepsy of 37 ± 10 min 
(Paakkari and Feuerstein, 1988). It is noteworthy that TAPS 
elicited dose-related antinociceptive effects also after i.v. or 
even p.o. administration. While maximal analgesia was ob-
tained by picomolar doses of TAPS i.c.v., 80% to 90% of the 
maximal possible analgesic effect was observed after i. v. injec-
tions of micromolar doses of TAPS. 
The TAPS-induced antinociception was an opioid receptor-
mediated effect because the effect was effectively abolished by 
naloxone. Moreover, naloxonazine attenuated TAPS-induced 
analgesia and catalepsy, which suggests that these effects are 
mediated by mu1 receptors because naloxonazine antagonizes 
binding at the mu1 sites in a long-lasting manner, whereas its 
binding to other opioid receptors is reversible (Hahn et al., 
1982; Ling et al., 1986). 
The doses of 3 pmol and 100 pmol of TAPS increased the 
ventilatory MV by 63% and 35%, respectively. A negative 
correlation was found between the TAPS dose and the respi-
ratory stimulant effect. However, even at a supramaximal anti-
nociceptive dose (300 pmol i.c.v.), TAPS did not depress res-
piration. An equianalgetic dose of morphine decreased the MV 
about 30%, mainly by decreasing the ventilatory TV. Like its 
analgesic and cataleptic effects, the respiratory stimulation 
induced by TAPS was antagonized by naloxonazine. 
Biochemical (Wolozin and Pasternak, 1981; Clarket al., 1988; 
Lutz et al., 1985; Blurton et al., 1986) and autoradiographic 
(Goodman and Pasternak, 1985; Moskowitz and Goodman, 
1985) receptor binding studies have suggested the existence of 
opioid mu receptor subtypes. In pharmacologicalstudies, opioid 
effects have been classified as naloxonazine-sensitive mu1 ef-
fects and naloxonazine-insensitive mtl2 effects (Pastemak and 
Wood 1986). Our present data lend further support to the 
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results of previous studies using naloxonazine or naloxazone 
that suggest that supraspinal analgesia and catalepsy are mu1 
receptor-mediated opioid effects, whereas respiratory depres-
sion (Ling et al., 1985), bradycardia (Holaday et al., 1983; 
Paakkari et al., 1992) and inhibition of guinea pig ileum con-
tractions or mouse gastrointestinal motility (Gintzler and Pas-
ternak, 1983; Heyman et al., 1988) are mediated by mfl2 recep-
tors. Moreover, our present study further extends the earlier 
findings by demonstrating that opioids acting on mu. receptors 
produce antinociception with respiratory stimulation. 
In a previous study, we demonstrated that dermorphin bad a 
biphasic effect on respiration. Low doses of dermorphin (3-10 
pmol i.c.v.) stimulated respiration, whereas doses greater than 
300 pmol shared the respiratory depressant effect of mu-opioid 
agonists (Paakkari et al., 1990). Naloxonazine antagonized the 
respiratory stimulating effect of very low doses of dermorphin 
while the respiratory depression produced by high dermorphin 
doses was potentiated (Paakkari et aL, 1990). A possible expla-
nation would be that, at low doses, the mu agonist dermorphin 
binds to high-affinity mu1 receptors only and that activation of 
these receptors induces respiratory stimulation. The suggestion 
that mu. receptors mediate respiratory stimulation (Paakkari 
et al., 1990) has been supported by studies in fetal lambs, in 
which naloxonazine increased the number of apneic episodes 
and pauses and reduced the regularity of the breathing pattern 
(Cheng et al., 1991). Furthermore, low doses of morphine were 
also shown to stimulate respiration measured with chronically 
implanted diaphragmatic electrodes. Morphine induced an in-
crease of diaphragmatic bursts, an increase or no change in 
breathing rate and a decrease in the number of apneic episodes 
per hour. All stimulatory effects were completely abolished 
with naloxonazine (Szeto et al., 1991). 
The potent antinociceptive, cataleptic and respiratory stim-
ulating mu. effects of TAPS are in concordance with the 
cardiovascular actions of this tetrapeptide. Low doses ofT APS 
(3-30 pmol i.c.v.) induced profound naloxonazine-sensitive 
tachycardia in the rat. Even with relatively high doses, TAPS 
induced less mll2-mediated bradycardia than dermorphin 
(Paakkari et al., 1992). 
Furthermore, TAPS produced, despite intense antinocicep-
tion, clearly less dependence than morpbine. Abrupt with-
drawal produced only slight loss of body weight and naloxone-
precipitated withdrawal signs were less intense than in mor-
phine-treated rats (Nakata et al., 1986). The authors found it 
incomprehensible that a large dose of TAPS (64 times the 
ED60) could not substitute for morpbine in preventing with-
drawal-induced weight lose, regardless of its high affinity for 
the mu receptors. This might be explained by the hypothesis 
that the withdrawal signs are mfl2 mediated, as suggested by 
Ling et al. (1984), and TAPS acts preferentially as a mu. 
agonist. It is also noteworthy that, even at these large doses of 
TAPS, this effect may be due to cross tolerance with morphine. 
However, the Iack of mortality after TAPS administration 
could be due to the absence of respiratory depression, a mll2 
receptor-mediated effect. 
To study the possibility that TAPS might act as a partial 
agonist at the mll2 receptor, we tested whether TAPS would 
block dermorphin-induced respiratory depression. Pretreat-
ment with TAPS (30 pmol i.c.v.) converted the 22 ± 10% 
decrease of MV induced by 3 nmol of dermorphin to a 44 ± 
11% increase of the MV and the effect of a higher dose of 
dermorphin was significantly reduced. The possibility that the 
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antagonistic effect would be due to stimulation of the mu1 
receptor was further studied by blocking the mu1 sites with 
naloxonazine. After the combined naloxonazine-TAPS pre-
treatment, dermorphin neither stimulated nor depressed ven-
tilation, suggesting that both mu receptor subtypes were 
blocked. A stimulatory dose of 10 pmol of dermorphin did not 
antagonize the respiratory depressant effect of a higher dose of 
dermorphin. This implies that the reduced ventilatory depres-
sion after TAPS pretreatment was not due to a rapid develop-
ment of tolerance. Acute tolerance would not be plausible, 
anyhow, because Ling et al. (1989) demonstrated that no sig-
nificant tolerance developed to mfl2 actions (respiratory depres-
sion and gastrointestinal transit) during a 10-hr morphine 
infusion, whereas mu1 actions (analgesia and prolactin release) 
diminished rapidly. 
Preliminary binding studies in our laboratory indicated that 
the Ki values for TAPS at mu. and m~ opioid binding sites 
were 0.4 and 1.3 nM, respectively. In the presence of guanosine 
nucleotides, the affinity of TAPS at the mu1 site was reduced 
significantly more than at the m~ site, which may indicate a 
partial agonistic activity at the mll2 site (S. Vonhof et al., 
manuscript in preparation). 
Tbe present data demonstrated that TAPS, produced strong 
and long-lasting analgesia without respiratory depression in 
the rat. This would be the profile of an ideal analgesic drug if 
these effects can be obtained in higher species as weil. As a 
possible mll2 antagonist, TAPS should induce less side effects, 
such as inhibition of gastric motility or physical dependence, 
the latter of which has been shown in the rat (Nakata et al., 
1986). TAPS induced antinociception also i.v. and p.o., which 
would make it even more useful as a possible analgesic. 
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